Physician profile
Sara Jordan
NPI 1902085822
$3,344.11
in general payments reported to CMS, 2019-2025
23 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,119 · 2020: $91.50 · 2022: $215 · 2024: $585 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.62 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,922.98 | 2019 | |
| Genmab U.S., INC. | $365.65 | 2022-2025 | Tivdak |
| Novartis Pharmaceuticals Corporation | $208.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $136.64 | 2019-2025 | Lynparza, Enhertu |
| Janssen Biotech, INC. | $78.88 | 2024-2025 | Darzalex, Rybrevant, Tecvayli |
| Tesaro, INC. | $77.74 | 2019 | |
| Daiichi Sankyo INC. | $69.60 | 2024 | Enhertu, Vanflyta |
| Myriad Genetic Laboratories, INC. | $64.53 | 2020 | |
| Exelixis INC. | $50.52 | 2019-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $45.46 | 2024-2025 | Keytruda, Lynparza |
| Sobi, INC | $38.67 | 2024 | |
| Abbvie INC. | $34.12 | 2025 | |
| Dendreon Pharmaceuticals LLC | $33.52 | 2025 | Provenge |
| Genentech USA, INC. | $27.87 | 2024 | Perjeta, Itovebi, Phesgo |
| Geron Corporation | $25.75 | 2024 | Rytelo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $25.12 | 2025 | |
| Abbott Laboratories | $24.03 | 2025 | Jot Dx |
| Puma Biotechnology, INC. | $23.42 | 2019 | |
| Karyopharm Therapeutics INC. | $22.98 | 2024 | Xpovio |
| Eisai INC. | $21.99 | 2024 | |
| Genzyme Corporation | $18.43 | 2024 | |
| Gilead Sciences, INC. | $14.02 | 2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.